A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Summary

The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-06 and to characterize the safety and tolerability of EMB-06 at the RP2Ds. Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-06 will also be assessed.

Timeline

Start

2021-05-20

Primary completion

2024-08-20

Completion

2024-08-20

Outcome

Outcome not reported

Stopped: “Company's resource optimization and product's development change”

Drugs

Indications